Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
about
Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II studyPotent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine KinasePaclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer.Elevated reticulocyte count--a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case reportSingle-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancerPhase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II study[Phase II trial of improved regimen with gemcitabine in patients with advanced non-small cell lung cancer].A phase II study of first-line chemotherapy with weekly carboplatin plus gemcitabine in advanced non-small cell lung cancer.Gemcitabine for the treatment of advanced nonsmall cell lung cancerAerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogsPharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer.Phase II study of gemcitabine in patients with advanced pancreatic cancer.The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).Lung cancer--where are we today? Current advances in staging and nonsurgical treatment.Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancerThe role of gemcitabine in the treatment of other tumoursIn vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer.Phase I study of gemcitabine using a once every 2 weeks schedule.Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer.First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial.Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: retrospective analysis of 124 patients.New insights into the synergism of nucleoside analogs with radiotherapyCSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.Bayesian survival analysis in clinical trials: What methods are used in practice?New antimetabolites in cancer chemotherapy and their clinical impactInterleukin 6 is a cause of flu-like symptoms in treatment with a deoxycytidine analogue.Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study.Promising new agents in the treatment of non-small cell lung cancer.Fatal pulmonary toxicity resulting from treatment with gemcitabine.Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: a phase II multicenter trial.New Agents in the Management of Non-Small Cell Lung Cancer.A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer.Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.
P2860
Q28364203-24BF2E52-2994-47D3-8353-9709F59C13B5Q28550404-D29DA612-EE71-4F64-B225-33D94A13059EQ31791219-690C7B90-3364-40F9-9A9D-DA874F19620DQ31927266-8391BE35-8253-4068-914C-F10967F63540Q33328421-275C680F-6F36-459E-97DF-FBAC5D47E0A3Q33330549-4F0BDECA-AD99-4D43-8BD4-80737B76E2F0Q33334777-E3BFC458-E044-4012-8694-70B03890CC00Q33360840-3389502E-D7B1-4BA9-8222-E5F4BD0CE289Q33366782-158D1D3C-7797-4480-9E38-93DED7101F9AQ33389166-E1CADDCB-11DC-42A3-839E-DA204B146C2BQ33399148-BB8443A3-7EA7-45C3-800C-E26AE8932720Q33399989-8D133D93-4938-40DD-A7BA-DF0FE363AE07Q33915997-820FB12C-653A-4937-A691-7A1B7E9BF579Q33926491-61419F66-4015-4527-9245-9CE5E68D8DB5Q34425234-25825B49-74F3-4CF4-8F74-9DC719458B11Q34732138-04F90A1C-D72E-4EF0-9C32-9D602F4479EDQ34791240-285DA50A-9CB3-4956-BE47-D075345EBE57Q34982142-E0D111CE-15B2-485F-BE73-EE5101E56E0EQ35768318-A9163B40-6F0F-4D0A-9E3E-B2826858CA06Q36114500-CF23964A-EA5E-4016-8CF3-FC6537405140Q36116478-DFDF89D8-5CA1-46D9-8BC4-E5885407807CQ36135699-07BD755E-482F-4AC8-B241-AF4610EFB778Q36431498-4E816DDB-A1CD-4AB6-BE6A-6ABEB4DDC9BEQ36614893-AC763A0E-3736-4547-878F-DD6B722F21F0Q36671151-91EF0EF3-A00F-4A68-A92A-75D389FFC1B5Q37341664-6E5E7EA6-B4C9-4FC8-8601-B876550C2669Q38143241-34FEB9BB-4C2B-499E-A090-199CF2558066Q38768945-AF05E7CD-C6E6-47A7-8692-446710B6B7EBQ38978314-488C8766-3295-40E1-894B-F6B0326E94E7Q39702086-820E8873-A887-4D9E-B346-3694489117A5Q39707448-7ED5FCDE-4902-46E5-817F-09A97416F884Q40754903-34A1620A-3CA3-480C-85DA-59291FE2C811Q40969505-FA8457E4-8E1A-4FEC-88C4-5C6A690E573AQ41525802-D5FA563A-5DEA-4B93-9565-8B37E622993BQ43732866-14EA5379-75F4-4621-B187-97FE83A414CAQ47620441-8F9F18CA-035E-4B4A-9C4C-7704DE3364BAQ47715936-700A1B1C-4199-4966-B80E-6C2929574129Q54650178-3F388C42-230A-4608-B094-6F86C4A41997
P2860
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
description
1994 nî lūn-bûn
@nan
1994 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Single-agent activity of weekl ...... lung cancer: a phase II study.
@ast
Single-agent activity of weekl ...... lung cancer: a phase II study.
@en
type
label
Single-agent activity of weekl ...... lung cancer: a phase II study.
@ast
Single-agent activity of weekl ...... lung cancer: a phase II study.
@en
prefLabel
Single-agent activity of weekl ...... lung cancer: a phase II study.
@ast
Single-agent activity of weekl ...... lung cancer: a phase II study.
@en
P2093
P1476
Single-agent activity of weekl ...... lung cancer: a phase II study.
@en
P2093
P304
P356
10.1200/JCO.1994.12.9.1821
P407
P577
1994-09-01T00:00:00Z